Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Lymphoma
About this trial
This is an interventional treatment trial for Lymphoma focused on measuring Waldenström macroglobulinemia
Eligibility Criteria
DISEASE CHARACTERISTICS: Waldenstrom's macroglobulinemia confirmed by the following: Bone marrow lymphoplasmacytosis with: Greater than 10% lymphoplasmacytic cells OR Aggregates, sheets, lymphocytes, plasma cells, or lymphoplasmacytic cells on bone marrow biopsy AND Measurable disease defined as quantitative IgM monoclonal protein greater than 1,000 mg/dL Bone marrow lymphoplasmacytosis and beta-2 microglobulin in the serum are not considered measurable Impaired bone marrow function due to infiltration by lymphoplasmacytic lymphoma Hemoglobin less than 11 g/dL OR Serum viscosity level relative to water greater than 4.0 Symptomatic with clinically significant anemia (less than 11 g/dL), bulky lymphadenopathy that is symptomatic, or symptoms attributable to hyperviscosity (e.g., nose bleeding, gingival bleeding, retinal hemorrhage) PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 Life expectancy: Not specified Hematopoietic: See Disease Characteristics Hepatic: SGOT less than 3 times upper limit of normal Bilirubin less than 2.0 mg/dL Renal: Creatinine no greater than 3.0 mg/dL Cardiovascular: No myocardial infarction within past 6 months No significant arrhythmia within past 3 months Hypertension allowed provided controlled with medication Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception Concurrent reversible complications (e.g., hyperuricemia, hyperviscosity) allowed provided therapy for complication initiated and complications subsiding Other prior malignancies allowed provided curatively treated and currently disease free PRIOR CONCURRENT THERAPY: No more than 2 prior regimens allowed Prior tandem transplant considered 2 prior regimens Chemotherapy prior to bone marrow transplantation as part of induction considered 1 prior regimen Retreatment with same regimen (e.g., repeated alkylating agents) considered 1 prior regimen Biologic therapy: No prior anti-CD20 therapy At least 1 month since prior epoetin alfa No concurrent epoetin alfa for 2 months after registration Chemotherapy: At least 28 days since prior alkylating agents At least 28 days since prior purine nucleoside analogues Endocrine therapy: At least 28 days since prior corticosteroid therapy Radiotherapy: At least 4 weeks since prior radiotherapy Surgery: Not specified Other: Concurrent digoxin to control atrial fibrillation allowed
Sites / Locations
- CCOP - Scottsdale Oncology Program
- Cancer Center and Beckman Research Institute, City of Hope
- Veterans Affairs Medical Center - Palo Alto
- Stanford University Medical Center
- CCOP - Colorado Cancer Research Program, Inc.
- CCOP - Christiana Care Health Services
- Walter Reed Army Medical Center
- Veterans Affairs Medical Center - Gainsville
- H. Lee Moffitt Cancer Center and Research Institute
- Veterans Affairs Medical Center - Tampa (Haley)
- Emory University Hospital - Atlanta
- Veterans Affairs Medical Center - Atlanta (Decatur)
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
- Veterans Affairs Medical Center - Lakeside Chicago
- CCOP - Central Illinois
- CCOP - Evanston
- CCOP - Illinois Oncology Research Association
- CCOP - Carle Cancer Center
- Indiana University Cancer Center
- Veterans Affairs Medical Center - Indianapolis (Roudebush)
- CCOP - Cedar Rapids Oncology Project
- CCOP - Iowa Oncology Research Association
- Holden Comprehensive Cancer Center at The University of Iowa
- MBCCOP - LSU Health Sciences Center
- CCOP - Ochsner
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Beth Israel Deaconess Medical Center
- CCOP - Ann Arbor Regional
- CCOP - Kalamazoo
- CCOP - Duluth
- Veterans Affairs Medical Center - Minneapolis
- University of Minnesota Cancer Center
- Mayo Clinic Cancer Center
- CCOP - Metro-Minnesota
- CCOP - Missouri Valley Cancer Consortium
- CCOP - Southern Nevada Cancer Research Foundation
- Veterans Affairs Medical Center - East Orange
- CCOP - Northern New Jersey
- Cancer Institute of New Jersey
- Veterans Affairs Medical Center - Albany
- Albert Einstein Comprehensive Cancer Center
- MBCCOP-Our Lady of Mercy Cancer Center
- Veterans Affairs Medical Center - Brooklyn
- Veterans Affairs Medical Center - New York
- NYU School of Medicine's Kaplan Comprehensive Cancer Center
- CCOP - Merit Care Hospital
- Ireland Cancer Center
- Veterans Affairs Medical Center - Cleveland
- Cleveland Clinic Taussig Cancer Center
- CCOP - Columbus
- CCOP - Toledo Community Hospital Oncology Program
- CCOP - Sooner State
- Hahnemann University Hospital
- University of Pennsylvania Cancer Center
- Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
- Fox Chase Cancer Center
- University of Pittsburgh Cancer Institute
- Veterans Affairs Medical Center - Pittsburgh
- Guthrie Medical Center
- CCOP - MainLine Health
- CCOP - Sioux Community Cancer Consortium
- Veterans Affairs Medical Center - Nashville
- Vanderbilt-Ingram Cancer Center
- Veterans Affairs Medical Center - Madison
- University of Wisconsin Comprehensive Cancer Center
- CCOP - Marshfield Medical Research and Education Foundation
- MBCCOP - San Juan
- Veterans Affairs Medical Center - San Juan
- Pretoria Academic Hospitals